N,N-dimethyl-N'-(quinolin-2-yl)ethane-1,2-diamine | 75308-36-0

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 喹啉及其衍生物
• 英文名称: N,N-dimethyl-N'-(quinolin-2-yl)ethane-1,2-diamine
• 英文别名: 2-chloroquinoline；2-(2-dimethylaminoethylamino)quinoline；2-(2-Dimethylamino-ethylamino)-chinolin；N',N'-dimethyl-N-quinolin-2-ylethane-1,2-diamine
• CAS: 75308-36-0
• 化学式: C₁₃H₁₇N₃
• mdl: MFCD11123271
• 分子量: 215.298
• InChiKey: FSCKKQPHNYTTGE-UHFFFAOYSA-N

物化性质

• 熔点：
  25-28 °C
• 沸点：
  170-175 °C(Press: 0.6 Torr)
• 密度：
  1.115±0.06 g/cm3(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  2.1
• 重原子数：
  16
• 可旋转键数：
  4
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.307
• 拓扑面积：
  28.2
• 氢给体数：
  1
• 氢受体数：
  3

反应信息

• 作为反应物：
  描述：

  N,N-dimethyl-N'-(quinolin-2-yl)ethane-1,2-diamine 以55%的产率得到N,N-Dimethyl-N'-(2-dimethylaminoethyl)-N'-(2-quinolyl)urea Hydrochloride
  参考文献：
  名称：

  Pyridinyl ureas and pharmaceutical use

  摘要：

  发现具有通式##STR1##的化合物能够抑制哺乳动物的胃分泌。

  公开号：

  US04203988A1
• 作为产物：
  描述：

  2-氯喹啉 、 N,N-二甲基乙二胺 反应 12.0h， 以41%的产率得到N,N-dimethyl-N'-(quinolin-2-yl)ethane-1,2-diamine
  参考文献：
  名称：

  [EN] KINASE PROTEIN BINDING INHIBITORS
  [FR] INHIBITEURS DE LA LIAISON À UNE PROTÉINE KINASE

  摘要：

  这项发明涉及蛋白结合抑制剂化合物及其识别和使用方法。该发明还涉及制药组合物和治疗细胞增殖性疾病，特别是癌症的方法。

  公开号：

  WO2013074517A1

文献信息

• Platelet adenosine diphosphate receptor antagonists
  申请人：Bryant A. Judi

  公开号：US20050065163A1

  公开（公告）日：2005-03-24

  Compounds of the following formula (I): where a, b, R 1 , R 2 , R 3 , R 4 and R 6 are described herein, are useful as inhibitors of platelet adenosine diphosphate. Pharmaceutical compositions containing these compounds, methods of using these compounds as antithrombotic agents and processes for synthesizing these compounds are also described herein.

  以下化学式(I)所描述的化合物，其中a、b、R1、R2、R3、R4和R6，可用作抑制血小板腺苷二磷酸的抑制剂。本文还描述了含有这些化合物的制药组合物、使用这些化合物作为抗血栓剂的方法以及合成这些化合物的过程。
• Design, synthesis, and biological evaluation of novel FAK scaffold inhibitors targeting the FAK–VEGFR3 protein–protein interaction
  作者：Priyanka N. Gogate、Manivannan Ethirajan、Elena V. Kurenova、Andrew T. Magis、Ravindra K. Pandey、William G. Cance

  DOI：10.1016/j.ejmech.2014.04.041

  日期：2014.6

  Focal adhesion kinase (FAK) and vascular endothelial growth factor receptor 3 (VEGFR3) are tyrosine kinases, which function as key modulators of survival and metastasis signals in cancer cells. Previously, we reported that small molecule chlorpyramine hydrochloride (C4) specifically targets the interaction between FAK and VEGFR3 and exhibits anti-tumor efficacy. In this study, we designed and synthesized a series of 1 (C4) analogs on the basis of structure activity relationship and molecular modeling. The resulting new compounds were evaluated for their binding to the FAT domain of FAK and anti-cancer activity. Amongst all tested analogs, compound 29 augmented anti-proliferative activity in multiple cancer cell lines with stronger binding to the FAT domain of FAK and disrupted the FAK-VEGFR3 interaction. In conclusion, we hope that this work will contribute to further studies of more potent and selective FAK-VEGFR3 protein-protein interaction inhibitors.
• Process for preparing 2-alkylamino- and 2-amino-5-alkylpyridines
  申请人：REILLY INDUSTRIES, INC.

  公开号：EP0091790B1

  公开（公告）日：1989-11-15
• KINASE PROTEIN BINDING INHIBITORS
  申请人：ROSWELL PARK CANCER INSTITUTE

  公开号：US20150051245A1

  公开（公告）日：2015-02-19

  The invention relates to protein binding inhibitor compounds and methods of identifying and using them. The invention further relates to pharmaceutical compositions and methods for treating cell proliferative disorders, especially cancer.
• US4203988A
  申请人：——

  公开号：US4203988A

  公开（公告）日：1980-05-20